COMMON HUB GENES AND DRUG CANDIDATES FOR DIABETIC KIDNEY DISEASE AND NON-ALCOHOLIC FATTY LIVER DISEASE: A COMPREHENSIVE BIOINFORMATIC STUDY
Abstract
Diabetes mellitus (DM) is one of the most prevalent diseases responsible for worldwide morbidity and mortality. The kidney and liver are the most commonly affected organs resulting in diabetic kidney disease (DKD) and non-alcoholic fatty liver disease (NAFLD). However, pathophysiological mechanisms that may be common to both DKD and NAFLD have not been elaborated despite having a common underlying cause. This study aimed to identify the hub genes that are common to both DKD and NAFLD and explore the potential drugs for their treatment. Gene expression datasets for DKD and NAFLD from the gene expression omnibus database were analyzed to identify differentially expressed genes (DEGs). A functional enrichment analysis of the DEGs was done to reveal pathways important in the etiology of DKD and NAFLD. Protein-protein interaction (PPI) network was constructed and hub genes were identified. The hub genes were further analyzed to identify potentially viable drug candidates after screening. A total of 89 DEGs were found to be common between DKD and NAFLD. Functional enrichment of said DEGs found Ppar, FoxO signaling and hepatocellular carcinoma pathways to be most prevalent in DKD and NAFLD. From the PPI network, 32 common hub genes were identified. The hub genes were analyzed for interacting drugs. Finally, 9 drugs were identified as potential candidates for the treatment of both diseases. The hub genes identified can provide new insights into the common etiology of DKD and NAFLD. The potentially viable drugs may be repurposed for the treatment of both DKD and NAFLD.
Keywords:
Diabetes, Diabetic kidney disease, Non-alcoholic fatty liver disease, Differentially expressed genes, Hub genesDOI
https://doi.org/10.25004/IJPSDR.2024.160114References
WHO Fact Sheet. September 16, 2023. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014; 37(Supplement_1): S81-90.
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JC, Mbanya JC, Pavkov ME. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022; 183:109119.
Atlas D. International diabetes federation. IDF Diabetes Atlas, 7th edn. 2015; 33(2).
Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10(4):284-96.
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J. Nephropharmacology. 2016; 5(1):49.
Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014; 9(3):126-33.
Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig. Liver Dis. 2015; 47(12):997-1006.
Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do diabetologists stand? Clin Diabetes Endocrinol. 2020; 6:1-1.
Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, Ortiz A. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin. Kidney J. 2020; 13(5):728-33.
Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2019;15(10):569-89.
Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin. Proc. 2011; 86(5):444-456.
Wang J, Xiang H, Lu Y, Wu T, Ji G. New progress in drugs treatment of diabetic kidney disease. Biomed. Pharmacother. 2021; 141:111918.
Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of diabetic kidney disease: current and future. Diabetes Metab J. 2021; 45(1):11-26.
Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic drugs in NAFLD: the accomplishment of two goals at once? Pharmaceuticals. 2018; 11(4):121.
Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, Bacic A. FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15(15):2597-601.
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma’ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013; 14(1):1-4.
Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44(W1):W90-7.
Xie Z, Bailey A, Kuleshov MV, Clarke DJ, Evangelista JE, Jenkins SL, Lachmann A, Wojciechowicz ML, Kropiwnicki E, Jagodnik KM, Jeon M. Gene set knowledge discovery with Enrichr. Curr. Protoc. 2021; 1(3):e90.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017; 7(1):42717.
Yu D, Lim J, Wang X, Liang F, Xiao G. Enhanced construction of gene regulatory networks using hub gene information. BMC Bioinform. 2017; 18(1):1-20.
He X, Yin J, Yu M, Qiu J, Wang A, Wang H, He X, Wu X. Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis. Am. J. Transl. Res. 2022; 14(9):6751.
Li Y, He X, Li C, Gong L, Liu M. Identification of candidate genes and microRNAs for acute myocardial infarction by weighted gene coexpression network analysis. Biomed Res. Int. 2019; 2019.
Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, Wadi L, Meyer M, Wong J, Xu C, Merico D. Pathway enrichment analysis and visualization of omics data using g: Profiler, GSEA, Cytoscape and EnrichmentMap. Nat. Protoc. 2019; 14(2):482-517.
Gou D, Liu R, Shan X, Deng H, Chen C, Xiang J, Liu Y, Gao Q, Li Z, Huang A, Wang K. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. J. Clin. Investig. 2023; 133(13).
Cai JJ, Liang MT, Li WQ, Zhang WY, Li X, Sun ZH. Preliminary study of PPARA regulate the ferroptosis of hepatocellular carcinoma to prevent disease deterioration. Zhonghua Yu Fang Yi Xue Za Zhi. 2023; 57(7):1068-74.
Tao L, Ding X, Yan L, Xu G, Zhang P, Ji A, Zhang L. CD36 accelerates the progression of hepatocellular carcinoma by promoting FAs absorption. Med. Oncol. 2022; 39(12):202.
Lin CL, Wang FS, Hsu YC, Chen CN, Tseng MJ, Saleem MA, Chang PJ, Wang JY. Modulation of Notch-1 signaling alleviates vascular endothelial growth factor–mediated diabetic nephropathy. Diabetes. 2010; 59(8):1915-25.
Yu R, Bo H, Huang S. Association between the PPARG gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. Genet Test Mol Biomarkers. 2012; 16(5):429-34.
Li Y, Hu Q, Li C, Liang K, Xiang Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Ambati CR, Putluri N. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. J. Clin. Investig. 2019; 129(3):1129-51.
Xia X. Bioinformatics and drug discovery. Curr Top Med Chem. 2017; 17(15):1709-26.
Published
Abstract Display: 361 
PDF Downloads: 300 
